Theravance Biopharma Inc TBPH 深 滬
等待開盤 09-17 09:30:00 美东时间
17.03
-0.010
-0.06%
華盛通- 最 高17.04
- 今 開17.04
- 成交量 46.17万股
- 最 低 17.02
- 昨 收 17.04
- 總市值 8.84亿
- 52周最高 21.03
- 市盈率 靜 8.28
- 換手率 0.89%
- 52周最低 13.08
- 委 比 -50.37%
- 總股本 5191.88万
- 歷史最高 43.44
- 量 比 1.38
- 振 幅 0.12%
- 歷史最低 6.10
- 每 手 1
- 風險率 1.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Catalyst Watch: FOMC blockbuster, Salesforce event, and 24-hour trading talk
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Read more about the events that may impact stock prices next week. Monday - September...
09-12 03:00
Theravance facing several lawsuits seeking to block Zymeworks acquisition
Theravance Biopharma (TBPH) is facing at least three lawsuits that aim to scuttle its planned $929M acquisition by Zymeworks (ZYME). The legal actions seek to enjoin Theravance from proceeding with th...
09-10 23:03
Theravance Biopharma issues disclosures amid Zymeworks merger
Theravance Biopharma ( ($TBPH) ) just unveiled an update. On June 28, 2026, The...
09-10 21:27
Zymeworks gains following addition to Citi catalyst watch
Zymeworks (ZYME) is up ~2% in Monday trading after Citi added the stock to its 90-day catalyst watch list. The bank sees shares rising due to an August 25 FDA action date for zanidatamab, sold as Ziih...
08-11 00:05
Theravance Biopharma Q2 Adj. EPS $0.18 Beats $0.05 Estimate, Sales $20.731M Miss $21.600M Estimate
Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.05 by 260 percent. This is a 325 percent increase over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $20.731 million...
08-10 20:35
Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026
Zymeworks Inc. announced it will report its second quarter 2026 financial results on August 6, 2026, after market close. Due to the proposed acquisition of Theravance Biopharma, the company will not host a second quarter earnings conference call. Zymeworks, a global biotechnology company, focuses on managing licensed healthcare assets and developing innovative biotherapeutics for diseases like cancer, inflammation, and autoimmune disorders. The c...
07-16 10:00
美股大行评级 | 最高800美元！16家大行首予SpaceX"买入"或"超配"评级；奥本海上调康宁目标价从210美元升至230美元
今日重点评级关注：Canaccord Genuity：维持AtaiBeckley"买入"评级，目标价从15美元升至17美元；Truist Securities：维持NUVATION BIO"买入"评级，目标价从12美元升至13美元
07-08 15:31
HC Wainwright & Co. Downgrades Theravance Biopharma to Neutral, Raises Price Target to $17
HC Wainwright & Co. analyst Douglas Tsao downgrades Theravance Biopharma (NASDAQ:TBPH) from Buy to Neutral and raises the price target from $15 to $17.
07-07 19:41
Theravance downgraded at Jones on Zymeworks acquisition
Jones Trading has downgraded Theravance Biopharma (TBPH) to hold from buy following the announcement earlier Monday that Zymeworks (ZYME) is acquiring the company in a $929M deal. Analyst Debanjana Ch...
06-30 02:36
